Heberprot-P registered in 23 countries

Source:  Granma
June 8 2016

by: Orfilio Peláez | orfilio@granma.cu

Ten years after receiving its health registration and approval to be used in the national health system, the medicine Heber¬prot-P has been used to treat over 55,000 Cuban patients nationwide, with positive  results

dr jorge berlanga acosta cuba.gifDeveloped by a team of experts led by Dr. Jorge Berlanga Acosta from the Center for Genetic Engineering and Biotechnology (CIGB), Heber­prot-P is an injectable medication used to treat advanced foot ulcers in diabetic patients by accelerating the healing process, thus reducing the risk of amputation in over 78% of cases.

The only one of its kind in the world – WIPO Gold Medal Winner

The only one of its kind in the world, the product received the Gold Medal awarded by the World Intellectual Property Organization (WIPO) and offers a novel therapeutic solution to a condition which previously lacked effective treatments.

Speaking to Granma, Iris Lugo, Heber Biotec S.A. enterprise’s communication specialist, stated that at a global level Heberprot-P has been used to help treat around 250,000 people and is registered in 23 countries, including Russia, Argentina, Venezuela, Turkey, Colombia, Ecuador, Ukraine and Vietnam.

Related:  Heberprot-P: a Synonym of Hope and Health for Thousands of Diabetics

Cuba to host First Regional Scientific Conference on Diabetes

Today there are more than 366 million people affected with this condition that kills 4.6 million people annually, which represents a challenge for health systems worldwide, according to WHO statistics.


World Diabetes Day (WDD) is celebrated every year on November 14. The World Diabetes Day campaign is led by the International Diabetes Federation (IDF) and its member associations. It engages millions of people worldwide in diabetes advocacy and awareness. World Diabetes Day was created in 1991 by the IDF and the World Health Organization (WHO) in response to growing concerns about the escalating health threat that diabetes now poses. World Diabetes Day became an official United Nations Day in 2007 with the passage of United Nation Resolution 61/225. The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public spotlight. 

World Diabetes Day is a campaign that features a new theme chosen by the International Continue reading

More Countries Show Interest in Cuban Medicine for Diabetic Patients

heberprot-p14 nations, including Russia, Brazil and China, are in the process of applying  to use in their hospitals Heberprot-P, a Cuban medicine which is the only one of its kind in the world capable of stimulating the growth of tissues and reversing acute lesions in the feet of diabetic patients.

Lawyer Erick Hernandez Leyva, a specialist of the Management Group for Promotion of the Center for Genetic Engineering and Biotechnology, said the drug has helped more than 200,000 people in Cuba and the world afflicted with diabetic foot ulcers in advanced and high risk of amputation.

Continue reading

Thousands Avoid Foot Amputation Thanks to New Cuban Medicine

Heberprot-P, a Cuban biomedicine for treating diabetic foot ulcers – the only of its kind in the world – will undergo phase III clinical trials this year in several hospitals in China and Russia. Administered locally into chronic wounds, Heberprot-P reduces the risk of amputation in diabetic foot ulcer patients, as it accelerates healing with human recombinant epithermal growth factor (hr-EGF). The drug was developed by scientists at the Center for Genetic Engineering and Biotechnology, (CIGB), Havana, jointly with the Institute of Angiology and Vascular Surgery.

According to Dr. Luis Herrera, director of the Center for Genetic Engineering and Biotechnology, the decision made by these two countries reflects the level of acceptance and effectiveness the product is enjoying in the world, as thousands of people have avoided amputation of the lower extremities thanks to this new product.
(photo: Dr. Luis Herrera)

Now in phase III of its development, Heberprot-P has a long impressive history. Since the 1990s, ongoing research and Continue reading

Ecuador Will Treat Foot Ulcers in Diabetic Patients with Cuba’s Heberprot-P

Recently, the Ecuadorian Health Ministry and the Cuban Heber Biotech Company agreed in Quito on the sale of some 9 000 doses of a new Cuban medication called Heberprot-P. The agreement was signed by Jorge Rodriguez, Cuba´s Ambassador to that South American nation, and Jose Maria Borja, Under Secretary of the local Foreign Ministry for Latin America and the Caribbean.

The first 500 Ecuadoran diabetic patients with foot ulcers are scheduled to be treated with this new Cuban medication, the only one of its type in the world capable of curing the ailment that otherwise could imply amputation.

Prensa Latina News Agency reported that the Cuban medical product is now being applied in Ecuador after the conclusion of the trial stage which was carried out with doses donated by Cuba.

90 percent effectiveness

During the signing ceremony, Jorge Mayo, representative of Biotech characterized the Continue reading